Piperacillin/tazobactam: A pharmacoeconomic review of its use in moderate to severe bacterial infections

PharmacoEconomics

Volumn 19, Issue 11, 2001, Pages 1135-1175

  Young, M ^a   Plosker, G L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; GENTAMICIN; METRONIDAZOLE; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; TEICOPLANIN; TIMENTIN; TOBRAMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HOSPITAL COST; HOSPITAL INFECTION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; NAUSEA; NEUTROPENIA; PHLEBITIS; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RASH; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

EID: 0035204769     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119110-00006     Document Type: Review

References (147)

1. Assessing antibacterial pharmacoeconomics in the intensive care unit
2. The use of systemic antibiotics in 7 community hospitals in Northern Israel
3. Antibiotic usage: Policy, clinical and pharmacoeconomic outcomes
4. Meropenem: A pharmacoeconomic review of its use in serious infections
5. The total process cost of parenteral antibiotic therapy: Beyond drug acquisition cost
6. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection
7. Cost comparison of antibacterial therapies for serious infections: A NZ 3-hospital study
8. Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia
9. Prescribing costs of piperacillin/tazobactam in comparison with cefotaxime/metronidazole and aminoglycoside combination therapy
10. Pharmacokinetic and economic evaluation of piperacillin/tazobactam administered as either continuous or intermittent infusion with once-daily gentamicin
11. New intervention strategies for reducing antibiotic resistance
12. Impact of targeted antibiotic restriction on usage and cost in a community hospital
13. Early impact of antimicrobiai management activities on antibiotic expenditures
14. Early switch from IV to oral antibiotics: Guidelines and implementation in a large teaching hospital
15. Management of community-acquired pneumonia: The role of clarithromycin
16. Hospital costs related to community acquired pneumonia
17. The patient-related cost of care for sepsis patients in a United Kingdom adult general intensive care unit
18. Economic impact of piperacillin/tazobactam in the treatment of suspected polymicrobial infections
19. Cost-effectiveness of quinolones in hospitals and the community
20. Use of broad spectrum beta-lactams (BSBL) in the ICU: The microbiologic adequacy (MAT) of regimens (Rgs) based on ceftazidime (CTZ), piperacillin/tazobactam (PIP/TZ), or imipenem (IMP), and outcomes of microbiologically inadequate treatment (MIT)
21. Cost-minimization analysis of piperacillin/tazobactam versus imipenem/ilastatin for the treatment of serious infections: A Canadian hospital perspective
22. The clinical failure rate of first-line antibiotic treatment is the key cost driver in community-acquired lower respiratory tract infections
23. Antibiotic policies: Economics and effectiveness from a UK perspective
24. Evaluation of rational use of antibiotics in Celal Bayar University Hospital
25. Use of antibiotics in intensive care units
26. Costs of nosocomial infections
27. The cost of antimicrobials for the treatment of nosocomial infections
28. Nosocomial infections in the ICU: The growing importance of antibiotic-resistant pathogens
29. Comparative cost-benefit in treating nosocomial and other infections in a general hospital
30. Epidemiology, therapy and costs of nosocomial infection
31. Incremental cost of disease in nosocomial pneumonia from a hospital's perspective: A feasibility study
32. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci
33. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary
34. Spread of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: Are beta-lactamase inhibitors of therapeutic value?
35. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella
36. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae
37. A comparison of piperacillin/tazobactam versus imipenem: Formulary considerations
38. Piperacillin/tazobactam: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
39. Piperacillin/tazobactam: An updated review of its use in the treatment of bacterial infections
40. Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries
41. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: A report from Austrian intensive care units
42. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
43. In vitro evaluation of cefepime and other broad-spectrum β-lactams against bacteria from Indonesian medical centers
44. In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates
45. In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of Gram-negative bacilli and Staphylococcus aureus
46. Susceptibility survey of piperacillin/tazobactam and some β-lactam comparators in Italy
47. In vitro evaluation of broad-spectrum β-lactams tested in medical centers in Korea: Role of fourth-generation cephalosporins
48. In vitro evaluation of cefepime and other broad-spectrum β-lactams for isolates in Malaysia and Singapore medical centers
49. In vitro evaluation of broad-spectrum β-lactams in the Philippines medical centers: Role of fourth-generation cephalosporins
50. In vitro evaluation of cefepime and other broad-spectrum β-lactams in eight medical centers in Thailand
51. Multicenter evaluation of the antimicrobial activity for six broad-spectrum β-lactams in Venezuela: Comparison of data from 1997 and 1998 using the Etest method
52. Efficacy and safety of piperacillin/tazobactam: Results of a postmarketing surveillance
53. Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia
54. Piperacillin/tazobactam in the treatment of lower respiratory tract infections: An open non-comparative and multicentered trial
55. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections
56. A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia
57. A comparative study of tazobactam/piperacillin and piperacillin in chronic respiratory tract infections
58. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection
59. Long-term hospitalization for tuberculosis control: Experience with a medical-psychosocial inpatient unit
60. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH)
61. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: A multicenter, randomized controlled trial
62. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection
63. Parenteral piperacillin/tazobactam combined with amikacin for the treatment of severe pulmonary infections in intensive care units
64. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis
65. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection
66. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections
67. The safety and efficacy of sequential (IV to PO) ciprofloxacin (CIP) plus metronidazole (MET) vs. piperacillin/tazobactam (PIP/TAZO) in the treatment of patients with complicated intra-abdominal (INTRAAB) infections
68. Multicenter randomized clinical trial of piperacillin plus tazobactam (TAZ) vs piperacillin plus tazobactam and amikacin (AMK) in the treatment of severe generalized peritonitis (SGP)
69. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections
70. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections
71. Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections
72. US officials consider how to curb growing antibiotic resistance
73. Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia
74. Piperacillin-tazobactam treatment for severe intra-abdominal infections
75. Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections
76. Randomized, double-blind, comparison efficacy study of piperacillin/tazobactam (PTZ) and imipenem/cilastatin (IPM) administered intravenously q8h to treat intra-abdominal infections (IAI)
77. A randomized, double-blind, multicenter comparison of the efficacy and safety of piperacillin/tazobactam (4g/500mg) and imipenem/cilastatin (1g/1g) administered intravenously every eight hours to treat intra-abdominal infections in hospitalized patients
78. Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections
79. A cost minimisation study comparing penicillin, gentamicin and metronidazole with piperacillin/tazobactam in the treatment of intra-abdominal sepsis in paediatrics
80. Piperacillin-tazobactam vs ciprofloxacin and amoxycillin in the treatment of infective episodes after liver transplantation: Prospective randomised multicentre study
81. Piperacillin/tazobactam versus cefotaxime plus metronidazole for the treatment of severe intra-abdominal infection in hospitalized pediatric patients
82. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
83. Piperacillin/tazobactam + amikacin versus ceftazidime + amikacin in neutropenic patients with fever: An open multicentric trial
84. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients
85. Impact of hospital-acquired infection on medical expenditures in geriatric rehability care
86. Do we need a triple antibiotic therapy?
87. Eight hourly scheduling of piperacillin-tazobactam (Tazocin) is equally effective in combination with either ciprofloxacin or an aminoglycoside for empiric therapy of neutropenic fever and is as effective as a 6 hourly treatment schedule
88. Cefepime + amikacin vs piperacillin/tazobactam plus amikacin for initial antibiotic therapy in hematological patients with febrile neutropenia: Results of an open, randomized multicenter trial
89. Helicobacter pylori screening and gastric cancer
90. Tick bites and Lyme disease in an endemic setting: Problematic use of serologic testing and prophylactic antibiotic therapy
91. Piperacillin-tazobactam plus netilmicin as empiric treatment for adult patients with acute leukemia, neutropenia, and fever: Single-center experience and retrospective comparison with piperacillin plus netilmicin
92. Piperacillin/tazobactam/gentamicin is a better initial empirical treatment than piperacillin/gentamicin in neutropenic pyrexia
93. Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients
94. Meningococcal vaccine in sub-Saharan Africa
95. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: A prospective randomized pilot study
96. Piperacillin/tazobactam vs. piperacillin/tazobactam plus amikacin as empiric therapy for fever in neutropenic patients
97. A randomized comparison of piperacillin-tazobactam vs. ceftriaxone and gentamicin in 172 severely neutropenic patients with hematologic malignancies
98. Detention of persistently nonadherent patients with tuberculosis
99. Pharmacoeconomic news from ICAAC
100. A randomized clinical trial with piperacillin/tazobactam (TAZ) and piperacillin/tazobactam in combination with netilmicin (TAZ/NET) in the treatment of fever of unknown origin in patients with severe neutropenia
101. Double-blind, randomized, clinical trial comparing monotherapy with piperacillin-tazobactam vs. piperacillin-tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients
102. Piperacillin/tazobactam in the treatment of serious acute soft tissue infection
103. Therapy of soft tissue infections with piperacillin/tazobactam
104. Treatment of hospitalized patients with complicated skin and skin structure infections: Double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate
105. Diagnosis, treatment, and prevention of Lyme disease
106. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections
107. Empirical antibiotic therapy in severe neutropenia. Ceftriaxone + amikacin vs piperacillin-tazobactam + amikacin
108. Piperacillin-tazobactam plus tobramycin is safe and effective therapy in children with febrile neutropenic episodes who are colonised with enterobacteriaceae expressing extended spectrum B-lactamases
109. A randomized prospective multicenter trial of cefpirome vs. piperacillin-tazobactam in febrile neutropenia
110. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients
111. The treatment of severe intra-abdominal infections: The role of piperacillin/tazobactam
112. An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections
113. Empiric therapy of bacterial infections in patients with severe neutropenia
114. A randomized study of clinafloxacin (CLX) and piperacillin/tazobactam (PIP/TZB) in severe skin and soft tissue infections
115. Piperacillin/tazobactam versus imipenem: A double-blind randomized formulary feasibility study at a major teaching hospital
116. Efficacy and safety of tazobactam/piperacillin in the treatment of bone and joint infections
117. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection
118. Piperacillin/tazobactam in complicated urinary tract infections
119. Antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): A prospective randomized clinical trial
120. Parenteral cephalosporin therapy in ambulatory care: Advantages and disadvantages
121. Randomized trial of piperacilin/tazobactam versus two regimens of ceftriaxone plus gentamicin in bone marrow transplant patients
122. The role of topical antibiotic prophylaxis in patients undergoing contaminated head and neck surgery with flap reconstruction
123. A multicentre study of the safety and efficacy of piperacillin/tazobactam plus tobramycin in the treatment of respiratory exacerbations in adult cystic fibrosis patients
124. Piperacillin/tazobactam. Committee on Antimicrobial Agents
125. Safety profile of piperacillin/tazobactam in phase I and III clinical studies
126. Clinical assessment and pharmacoeconomic analysis of adverse drug reactions of imipenem/cilastatin vs. piperacillin/tazobactam in adult febrile neutropenics
127. Invasive pneumococcal infections in children
128. Antibiotic-induced neutropenia in patients receiving community-based parenteral anti-infective therapy: Piperacillin/tazobactam vs ticarcillin/clavulanate
129. Immune thrombo-cytopenia caused by piperacillin/tazobactam
130. A silver bullet for colonization and infection with methicillin-resistant Staphylococcus aureus still eludes us
131. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage
132. Impact of trovafloxacin use on Gram-negative drug resistance in the surgical intensive care unit
133. Decreased antimicrobial resistance after changes in antibiotic use
134. Costs and outcomes of treating febrile neutropenia in nine European countries
135. Cost-effectiveness of piperacillin/tazobactam versus ceftazidime/amikacin for the treatment of febrile episodes in neutropenic cancer patients
136. Cost-effectiveness analysis of piperacillin-tazobactam versus imipenem-cilastatin in the treatment of intra-abdominal infections
137. Cost-effectiveness of piperacillin-tazobactam versus ceftazidime in patients with febrile neutropenia
138. Pharmacoeconomic evaluation of piperacillin and tazobactam versus standard treatment regimens for treatment of pneumonia and intraabdominal infections
139. Socioeconomic relevance of inpatient treatment of intra-abdominal infections with tazobactam/piperacillin 0.5g/4.0g in comparison with imipenem/cilastatin
140. Medical and economic relevance of treatment of febrile neutropenic cancer patients with piperacillin/tazobactam compared to ceftazidime
141. Medical and economic relevance of inpatient treatment of pneumonia with ceftriaxone in comparison to ciprofloxacin, meropenem and piperacillin/tazobactam
142. Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections
143. Hospital length of stay following surgery for intra-abdominal infection and treatment with piperacillin/tazobactam or imipenem/cilastatin
144. An economic evaluation of in-hospital use of piperacillin /tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infection
145. Socio-economic relevance of inpatient treatment of skin and soft tissue infections with tazobactam/piperacillin 0.5g/2.0g in comparison with amoxicillin/clavulanic acid, ceftriaxone, and cefotaxime